Announcement PDF Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 1 ASX ANNOUNCEMENT ACW Clinical Trials Science Forum webinar today – The future of Alzheimer’s disease treatment Sydney, 12 August 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) will host a live Clinical Trials Science Forum webinar at 11am (AEST) today. After an introduction by the Company’s CEO, Dr Steven Gourlay, Chief Commercial Officer, Andy Udell, will moderate a discussion on the future of Alzheimer's disease treatment with: • Prof. Marwan Sabbagh, internationally recognized neurologist and Alzheimer's disease specialist • Dr. Dana Hilt, Chief Medical Officer, Actinogen Medical. The webinar is intended to provide investors and other stakeholders with expert clinical perspectives on how Alzheimer's diagnosis and treatment are evolving, and what those changes could mean for future therapeutic approaches. The conversation will explore the rapidly evolving Alzheimer's treatment landscape, real-world experience with anti-amyloid therapies, the potential impact of blood-based biomarkers, and what physicians seek in next-generation Alzheimer’s therapies. Register any time this morning through to the 11am start at: https://tinyurl.com/yubcs5jr A recording of the webinar will be available on the Company’s website and YouTube channel following the event. A copy of the webinar presentation is attached to this announcement. View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/P3xxBy ENDS Investors Media Dr Steven Gourlay Michael Roberts George Hazim CEO & Managing Director Communications Media & Public Affairs Australia P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au Announcement authorised by the Disclosure Committee of Actinogen Medical Limited About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health. Cognitive function means how a person understands,remembers and thinks clearly.Cognitive functions include memory, attention, reasoning, awareness and decision-making. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 2 Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease. It has also conducted a phase 2 trial in patients with cognitive impairmentand depression andmay study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impactin these and many other diseases.The cognitive dysfunction,behavioural abnormalities,and neuropsychological burden associated with these conditions is debilitating for patients,and there is a substantial unmetmedical need for new and improved treatments. Clinical Trials The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 247 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood.Patients receive Xanamem 10 mg or placebo, once daily,and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints.The primary endpointof the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US and is now closed to participant recruitment. It has passed an independent Data Monitoring Committee safety and efficacy futility review and final topline results are expected in November 2026. The XanaMIA-OLE Alzheimer’s disease open-label extension is an open-label phase of up to 25 months treatment where all participants will receive active Xanamem 10 mg once daily. The trial evaluates safety and a limited number of efficacy endpoints such as the CDR-SB. The trial commenced in March 2026 and is open to all former and current participants in the XanaMIA Phase 2b/3 trial. The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressanttherapy,and effects on cognition and depressionwere assessed.Trial results were reported in August 2024 and showed clinically and statistically significantbenefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessmentof depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups. The peer-reviewed publication relating to this trial can be accessed for free via this link: https://tinyurl.com/ckm63z63. About Xanamem (emestedastat) Xanamem’s novel mechanism is to control elevated levels of cortisol (aka the “stress hormone”) in the brain through the inhibition of the cortisol synthesis enzyme,11β-HSD1,withoutaffecting production of cortisol by the adrenal glands which is essential for the body’s normal functioning.Xanamem is a first-in-class,once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex. To view Xanamem’s two-minute Mechanism of Action animation, click here. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms, further validating the cortisol control mechanism for the Xanamem 10 mg oral daily dose. The Company has studied 11β-HSD1 inhibition by Xanamem in more than 500 volunteers and patients in eight clinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression,patients with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. Xanamem is an investigational productand is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical. Disclaimer This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates,assumptions andqualifications;and relate to circumstances and events thathave nottaken place and may nottake place.Such forward looking statements should be considered “at-risk statements” - notto be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 3 economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements.You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievementor reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP. Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. This presentation is not for general distribution or third party reliance or use. This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward- looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends. To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation. 2 Clinical Trials Science Forum August 2026 Clinical Trials Science Forum August 2026 3 3 Clinical Trials Science Forum August 2026 Alzheimer’s is personal 5 Clinical Trials Science Forum August 2026 A disease that touches millions of patients, families and caregivers around the world Alzheimer’s is one of healthcare’s greatest challenges in the western world • 57 million people worldwide were living with dementia in 2021 • Alzheimer’s disease accounts for 60-70% of all dementia cases • Nearly 10 million new cases of dementia occur each year • 139 million people are projected to be living with dementia by 2050 6 Clinical Trials Science Forum August 2026 The growing global burden reinforces the need for continued innovation in Alzheimer’s disease A new era in Alzheimer’s disease has dawned • Disease-modifying therapies have begun to reshape the treatment landscape • Blood-based biomarkers have the potential to simplify the diagnosis and identify patients earlier • Scientific understanding continues to expand across multiple biological pathways • Earlier diagnosis and new treatment approaches may improve care for more patients 7 Clinical Trials Science Forum August 2026 Progress has begun, but the need for ongoing innovation remains Amyloid is a likely just a small part of the story ... Recent advances have provided hope for some Alzheimer’s patients… … but significant challenges remain: • Clinical benefit can be modest • Current therapies are not appropriate for all patients • Treatment and monitoring can be complex • Alzheimer’s disease is biologically complex and likely requires multiple therapeutic approaches. 8 Clinical Trials Science Forum August 2026 New mechanistic approaches are needed to address the diverse needs of patients living with Alzheimer’s disease Neurologists expect the Alzheimer’s landscape to continue evolving • 91% agree there remains a high unmet need for additional disease-modifying therapies • 86% expect the treatment of Alzheimer’s disease to change over the next five years “We’re not going to be just treating patients with an amyloid remover, but also anti-neuroinflammation, mitochondrial enhancers, synaptic enhancers and so on… in order to actually stop or substantially slow the progression of the disease.” --U.S. Neurologist 9 Clinical Trials Science Forum August 2026 We are just at the beginning of the journey towards understanding the biology of Alzheimer’s disease What do neurologists value most in Alzheimer’s therapies? Neurologists consistently value therapies that offer: • Meaningful clinical benefit i.e. slowing or halting disease progression • A favorable safety and tolerability profile • Simple, convenient administration • Broader patient eligibility • The potential to complement other therapies. 10 Clinical Trials Science Forum August 2026 Future Alzheimer’s therapies will need to deliver meaningful benefit while fitting seamlessly into clinical practice Attributes neurologists value for an Alzheimer’s therapy Attributes valued by neurologists Xanamem profile ✓ Meaningful clinical benefit Encouraging Phase 2 clinical efficacy signals* ✓ Favorable safety and tolerability Generally well tolerated in clinical trials ✓ Convenient administration Once-daily oral tablet ✓ Simplicity of treatment No infusion or routine MRI monitoring required ✓ Potential to complement other therapies Novel mechanism targeting excess brain cortisol, distinct from anti-amyloid therapies 11 Clinical Trials Science Forum August 2026 *Based on phase 2 clinical trials. XanaMIA phase 2b/3 topline results anticipated in November 2026 Xanamem’s profile aligns with the characteristics neurologists consider important for future Alzheimer’s therapies A different approach to Alzheimer’s disease Xanamem controls brain cortisol levels Unlike therapies that target amyloid, Xanamem targets excess brain cortisol by inhibiting the enzyme 11β-HSD1 Per extensive scientific literature, reducing excess brain cortisol has the potential to influence several processes associated with Alzheimer’s disease, including: • Cognition and memory • Neuroinflammation • Synaptic function • Tau biology. 12 Clinical Trials Science Forum August 2026 Targeting excess brain cortisol represents a unique and promising approach to Alzheimer’s disease The next chapter begins with the XanaMIA trial Pivotal, phase 2b/3 trial in 247 participants with mild-moderate disease Topline results anticipated in November 2026 If successful, Xanamem has potential to: • Expand therapeutic options for patients living with Alzheimer’s disease • Further validate brain cortisol control as a therapeutic mechanism • Contribute to the next generation of Alzheimer's disease treatment. 13 Clinical Trials Science Forum August 2026 XanaMIA represents an important milestone for patients, physicians, caregivers, and the future of Alzheimer’s disease treatment Clinical Trials Science Forum August 2026 14 14 Clinical Trials Science Forum August 2026 Contacts Will Souter CFO & Investor Relations M: +61 402 035 716 E. will.souter@actinogen.com.au Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au Join the Actinogen Investor Hub: https://investors.actinogen.com.au/ 15 Clinical Trials Science Forum August 2026